DermTech, Inc. DMTKQ
0.00
0.00
NaN
as of 13 Aug
- Market cap
- $3.3M
- P/E
- 0.0×
Follow DMTKQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '23 | Sep '23 | Dec '23 | Mar '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.89 | 3.46 | 3.54 | 1.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.56) | (2.61) | (4.26) | (1.40) | |
P/B ratio |
0.94 | 0.68 | 0.95 | 0.60 | |
Price to Tangible BV |
0.94 | 0.68 | 0.95 | 0.60 | |
EV/Sales |
(0.25) | (1.28) | (0.11) | (0.96) | |
EV/EBITDA |
0.03 | 0.17 | 0.02 | 0.17 | |
EV/Operating CF |
0.04 | 0.22 | 0.02 | 0.21 | |
EV/FCF |
0.04 | 0.21 | 0.02 | 0.21 | |
Quick Ratio |
5.62 | 5.68 | 4.35 | 3.31 | |
Current Ratio |
5.85 | 6.01 | 4.59 | 3.53 | |
Net Debt/EBITDA |
2.79 | 3.66 | 3.00 | 2.03 | |
Debt/Assets |
0.03% | 0.03% | 0.03% | 0.03% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.08 | 0.09 | 0.09 | 0.11 | |
Operating CF/Net income |
0.74 | 0.99 | 0.67 | 0.86 | |
Capex/Depreciation |
(0.20) | (0.04) | 0.14 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
97.66% | 91.83% | 85.32% | 84.94% | |
Selling, General and Administrative Expense of Revenue |
709.87% | 418.57% | 429.26% | 466.97% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
188.82% | 80.79% | 80.30% | 70.14% | |
Graham Net Nets |
0.30 | 0.22 | (0.06) | (0.78) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(150.00%) | (238.78%) | (189.16%) | (391.30%) | |
Free Cash Flow Yield |
(113.99%) | (177.93%) | (143.73%) | (304.72%) | |
Revenue per Share |
0.13 | 0.12 | 0.12 | 0.11 | |
Operating CF per Share |
(0.73) | (0.56) | (0.39) | (0.49) | |
Capex per Share |
(0.01) | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.74) | (0.56) | (0.38) | (0.49) | |
Cash per Share |
2.71 | 2.02 | 1.71 | 1.12 | |
Shareholders Equity per Share |
2.77 | 2.16 | 1.75 | 1.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.77 | 2.16 | 1.75 | 1.15 | |
Free Cash Flow |
(23.46) | (19.09) | (12.54) | (17.12) | |
Working Capital |
77.73 | 63.29 | 48.31 | 31.68 | |
Capital Expenditures |
(0.26) | (0.05) | 0.16 | — | |
Net Current Asset Value |
24.75 | 11.10 | (3.00) | (18.78) | |
EV/EBIT |
0.03 | 0.16 | 0.02 | 0.16 | |
Capex to Sales |
0.07 | 0.01 | (0.04) | 0.00 | |
Net Profit Margin |
(788.02%) | (489.50%) | (486.52%) | (520.42%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.91 | 4.85 | 3.38 | 3.09 | |
Average Payables |
1.59 | 2.35 | 1.95 | 1.80 | |
Average Inventory |
1.39 | 1.29 | 1.38 | 1.20 | |
Average Assets |
186.59 | 165.98 | 162.00 | 140.05 | |
Average Common Equity |
133.33 | 114.03 | 94.76 | 73.62 |
Columns are period end dates